Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Meeting Requests Increase, But FDA Cancels Some For Lack Of Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Some early meeting requests from potential biosimilar sponsors were not held because they did not include the necessary information for FDA to give development advice.

You may also be interested in...



Is FDA Reviewing A Biosimilar Marketing Application?

The agency changes its rhetoric on the subject, inviting speculation about whether a marketing application has been received.

Biosimilars: Does Low BsUFA Fee Revenue Suggest Sponsor Interest Has Stalled?

Halfway through the first year of the biosimilar user fee program, fee payments have not lived up to the expectation in President Obama’s FY 2013 budget request. Initial meetings continue to grow but at a slow pace, suggesting sponsors may remain hesitant about the pathway.

How To Get A Meeting With FDA: Guidance Describes Formal Meetings For Biosimilars

FDA’s fourth biosimilars-related guidance describes the formal meeting process for sponsors with products in development; the process will require extensive requests and information packages.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073616

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel